13F Holdings
中文EN

MXCT MAXCYTE, INC.

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1287098 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-0.1%
TTM net income YoY38.7%
TTM EPS YoY39.5%
Revenue 3-yr CAGR-3.3%
Net income 3-yr CAGR—

Margins

Gross margin81.0%
Operating margin-98.0%
Net margin-81.4%
FCF margin-62.4%
EBITDA margin-86.5%

Returns

ROE-16.9%
ROA-14.1%
ROIC (approx.)-17.5%
Asset turnover0.17x

Leverage & solvency

Liabilities / assets17.3%
Debt / equity0.00x
Current ratio7.83x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-3.5%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$33.03M$38.63M$41.29M$44.26M$33.89M
Cost of revenue$6.22M$7.10M$4.74M$5.10M$3.65M
Gross profit$26.80M$31.53M$36.55M$39.16M$30.25M
R&D expense$20.82M$22.23M$23.82M$19.51M$15.41M
SG&A expense$28.12M$29.69M$30.07M$25.83M$18.68M
Operating income-$51.90M-$51.20M-$48.30M-$27.36M-$18.19M
Interest expense————$5,400
Pretax income-$44.63M-$41.05M-$37.92M——
Income tax————$0
Net income-$44.63M-$41.05M-$37.92M-$23.57M-$19.08M
EBITDA-$47.56M-$46.88M-$44.13M-$24.66M-$16.76M
EPS (basic)-0.42-0.39-0.37-0.23-0.21
EPS (diluted)-0.42-0.39-0.37-0.23-0.21
Weighted avg. shares (diluted)106.43M104.85M103.27M101.70M90.62M
Balance sheet
Cash & equivalents$20.07M$27.88M$46.51M$11.06M$47.78M
Short-term investments$82.98M$126.60M$121.78M$216.28M$207.26M
Receivables$3.50M$4.68M$5.78M$11.18M$6.88M
Inventory$7.55M$8.91M$12.23M$8.58M$5.20M
Current assets$118.37M$171.68M$190.19M$252.27M$270.43M
PP&E, net$17.53M$19.71M$23.51M$23.73M$7.68M
Intangibles$650,000————
Total assets$202.51M$239.47M$268.27M$286.65M$284.12M
Current liabilities$14.27M$15.78M$17.86M$15.43M$15.62M
Total liabilities$31.02M$33.22M$36.11M$32.69M$21.22M
Shareholders' equity$171.49M$206.25M$232.17M$253.97M$262.90M
Shares outstanding106.79M105.71M103.96M102.40M101.20M
Cash flow statement
Operating cash flow-$34.41M-$27.61M-$21.69M-$14.78M-$10.68M
Capital expenditure$1.77M$1.65M$3.70M$18.48M$3.83M
Free cash flow-$36.18M-$29.26M-$25.39M-$33.26M-$14.51M
Investing cash flow$25.93M$6.93M$54.98M-$24.82M-$195.01M
Financing cash flow$656,000$2.06M$2.14M$2.89M$234.72M
Depreciation & amortization$4.34M$4.32M$4.17M$2.70M$1.42M
Stock-based compensation$9.21M$13.08M$13.98M$11.75M$7.96M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.